MedTrace Logo

Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma

NCT07315555 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-01-02

No results posted yet for this study

Summary

Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research

Conditions

  • Community Acquired Pneumonia

Interventions

DIETARY_SUPPLEMENT

Nigella sativa Oil Capsules (100 mg/kg/day)

Nigella sativa oil administered orally in capsule form at a dose of 100 mg/kg/day as adjunct therapy.

DIETARY_SUPPLEMENT

Nigella sativa Oil Capsules (50 mg/kg/day)

Nigella sativa oil administered orally in capsule form at a dose of 50 mg/kg/day as adjunct therapy.

DRUG

Fluticasone / Long-Acting Beta-2 Agonist Combination

Low-dose inhaled corticosteroid (fluticasone propionate 200 µg/day) combined with a long-acting beta-2 agonist (two puffs every 12 hours), administered via metered-dose inhaler with spacer.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-06-01
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07315555 on ClinicalTrials.gov